Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mergers and acquisitions
Biotech
89bio was left between a Roche and a hard place in buyout talks
Over three years, 89bio signed confidentiality agreements with 14 biopharmas as it advanced its MASH candidate.
Nick Paul Taylor
Oct 2, 2025 9:55am
Fierce Pharma
Halozyme buys Elektrofi for up to $900M
Oct 1, 2025 2:36pm
Genmab pays $8B to buy Merus and phase 3 bispecific
Sep 29, 2025 5:38am
Roche's obesity ambition not reliant on one megablockbuster
Sep 23, 2025 7:45am
Glooko buys Monarch’s EndoTool to enter in-patient diabetes care
Sep 23, 2025 7:30am
Pfizer inks $4.9B Metsera buyout to beef up obesity pipeline
Sep 22, 2025 7:47am
